Evidence map›Paper›PMID 28892571›Full record

ReviewTransplant international : official journal of the European Society for Organ Transplantation2017

Regenerative immunology: the immunological reaction to biomaterials.

Paolo Cravedi, Samira Farouk, Andrea Angeletti, Lauren Edgar, Riccardo Tamburrini, Jerome Duisit, Laura Perin, Giuseppe Orlando

Abstract readReview
In one paragraph

Review in Transplant international : official journal of the European Society for Organ Transplantation, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Immunomodulatory Delivery Materials for Tissue Repair.Advanced healthcare materials · 2025
    Review
  2. Article
  3. Comprehensive biocompatibility profiling of human pancreas-derived biomaterial.Frontiers in bioengineering and biotechnology · 2025
    Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. RNU (Bioengineering (Basel, Switzerland) · 2021
    Article
  10. Recent Advances in Kidney Bioengineering.Frontiers in pediatrics · 2021
    Review
  11. Engineered biomaterials for heart disease.Current opinion in biotechnology · 2020
    Review
  12. Review
  13. Review
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Paolo CravediDepartment of Medicine, Translational Transplant Research Center, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Samira FaroukDepartment of Medicine, Translational Transplant Research Center, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Andrea AngelettiDepartment of Medicine, Translational Transplant Research Center, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Lauren EdgarWake Forest University School of Medicine, Winston Salem, NC, USA.
Riccardo TamburriniWake Forest University School of Medicine, Winston Salem, NC, USA.
Jerome DuisitPôle de Chirurgie Expérimentale (CHEX), Institut de Recherche Expérimentale et Clinique (IREC), Université catholique de Louvain, Brussels, Belgium.
Laura PerinDivision of Urology, GOFARR Laboratory for Organ Regenerative Research and Cell Therapeutics, Saban Research Institute, Children's Hospital Los Angeles, University of Southern California, Los Angeles, CA, USA.
Giuseppe OrlandoWake Forest University School of Medicine, Winston Salem, NC, USA.ORCID http://orcid.org/0000-0002-9584-6927

Funding

Translational Immunology Training ProgramT32AI078892 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Karen Leigh Edelblum, SERGIO A. LIRA · 2008 to 2026
$4.5M
NIAID NIH HHS T32 AI078892
6 · The paper itself

Abstract

Regenerative medicine promises to meet two of the most urgent needs of modern organ transplantation, namely immunosuppression-free transplantation and an inexhaustible source of organs. Ideally, bioengineered organs would be manufactured from a patient's own biomaterials-both cells and the supporting scaffolding materials in which cells would be embedded and allowed to mature to eventually regenerate the organ in question. While some groups are focusing on the feasibility of this approach, few are focusing on the immunogenicity of the scaffolds that are being developed for organ bioengineering purposes. This review will succinctly discuss progress in the understanding of immunological characteristics and behavior of different scaffolds currently under development, with emphasis on the extracellular matrix scaffolds obtained decellularized animal or human organs which seem to provide the ideal template for bioengineering purposes.

Indexed as

Biocompatible MaterialsAnimalsBioengineeringForecastingGraft SurvivalHumansRegenerationRegenerative MedicineTissue ScaffoldsTransplantation, AutologousTransplantation, HomologousTransplantation ImmunologyBiocompatible MaterialsB cellextracellular matrixmacrophageneutrophilregenerative medicineT cell

Identifiers

PMID28892571
PMCPMC6697146

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.